Amrad in research collaboration with Merck Sharp & Dohme
23 June, 2003 by Melissa TrudingerMelbourne biotechnology company Amrad has formed a research collaboration with Merck Sharp & Dohme (MSD) with a total worth of $US112 million plus royalties to develop therapeutic drugs for asthma, respiratory diseases and cancer, the company announced today at the BIO2003 conference in Washington DC.
OGTR stops clock on GM canola
20 June, 2003 by Melissa TrudingerThe OGTR has stopped the clock for a second time on Bayer CropScience's application for commercial release of its InVigor genetically modified canola.
PsiMedica enters revenue sharing agreement
19 June, 2003 by Melissa TrudingerPerth nanotechnology company PsiVida announced that its British subsidiary PsiMedica has entered into a revenue sharing agreement with Texas Christian University (TCU) over an invention with applications in orthopaedics and tissue engineering.
Bio Pharma signs $3.5m contract
18 June, 2003 by Pete YoungA $3.5 million dollar conditional contract with an Asian company could give startup Bio Pharma Pty Ltd the push it needs to move into commercial production.
Peptech reports 'outstanding' results
18 June, 2003 by Jeremy TorrBiotech Peptech announced what it described as "outstanding" results from pre-clinical trials on its anti-Tumour Necrosis Factor (anti-TNF) antibody as a treatment for rheumatoid arthritis (RA).
Imugene completes $2m placement
17 June, 2003 by Melissa TrudingerVeterinary biotechnology company Imugene has completed a $AUD2 million placement to institutional and professional high net worth investors.
Genetic Technologies receives $US150,000 for patent license
16 June, 2003 by Melissa TrudingerTexan company Inguran has paid $US150,000 to Melbourne-based Genetic Technologies to use the company's non-coding patents for genetic testing of livestock in the USA, Colombia and Brazil.
Laser lab to improve artificial heart design
13 June, 2003 by Jeremy TorrA $1.5million laser diagnostic laboratory could help researchers cut down thrombosis risks for artificial heart patients, using the latest Particle Image Velocimetry (PIV).
Tissue Growth and Repair CRC backs a winner
13 June, 2003 by Jeremy TorrShooting the nag for not winning could be a thing of the past thanks to the CRC for Tissue Growth and Repair’s work on IGF-I (insulin-like growth factor-I) to stimulate tissue repair.
Imugene itching to launch product
12 June, 2003 by Jeremy TorrVet biotech Imugene is pinning big hopes on its recombinant gene-based flea control vaccine currently on trial at Murdoch University.
Genetraks invests $1m to fast-track development
11 June, 2003 by Pete YoungCashed-up young biotech Genetraks Pty Ltd is investing more than $1 million to dramatically accelerate the time to market of its gene-based diagnostic and monitoring tools.
MIF blocking drugs being developed by Cortical
11 June, 2003 by Melissa TrudingerOne of Australia's newest start-up companies has spun out of Monash University with a focus on finding therapeutics targeting the macrophage inhibitory factor (MIF).
GM's lambs are inviting slaughter
11 June, 2003 by Graeme O'NeillGraeme O'Neill discovers that the biotech community needs a whole new strategy to win points on GM crops
Africa needs GM crops: scientist
10 June, 2003 by Graeme O'NeillAfrican plant geneticist Dr Florence Wambugu has accused Western activists, seeking to block the introduction of genetically modified (GM) crops in Africa, of having “no understanding” of the needs of African farmers and communities.
GroPep, CSL amend agreement
10 June, 2003 by Melissa TrudingerAdelaide company GroPep and cell culture reagent distribution partner CSL have amended their sales and distribution agreement to reflect expected demand for GroPep's growth factor products by extending the agreed minimum sales targets from the 2005-2006 financial year through to the end of the 2010 financial year, when the agreement ends.
